Lexeo Gets FDA Fast-Track Designation for LX2006 in Friedreich's Ataxia Cardiomyopathy
By Colin Kellaher
Lexeo Therapeutics has won U.S. Food and Drug Administration fast-track designation for its LX2006 gene therapy candidate for the most common cause of death in people with a rare genetic neuromuscular disorder.
Lexeo on Tuesday said the designation covers LX2006 in the treatment of cardiomyopathy in patients with Friedreich's ataxia, an inherited disorder that causes progressive damage to the nervous system.
The FDA's fast-track program is designed to facilitate the development and expedite the review of treatments for serious or potentially life-threatening illnesses with high unmet medical needs.
Lexeo, which previously won FDA rare-pediatric-disease and orphan-drug designations for LX2006 in the treatment of Friedreich's ataxia cardiomyopathy, said it is currently conducting a Phase 1/2 study to evaluate the safety, tolerability and preliminary efficacy of the gene therapy.
The New York clinical-stage genetic-medicine company said there are currently no FDA-approved treatment options for Friedreich's ataxia cardiomyopathy.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 16, 2024 08:04 ET (12:04 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks